Cite
HARVARD Citation
Quoix, E. et al. (n.d.). TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet oncology. 17 (2), pp. 212-223. [Online].